摘要
背景:活化小胶质细胞通过产生多种促炎介质,包括对神经元和少突胶质细胞有毒的肿瘤坏死因子-α(TNF-α),白细胞介素-1β(IL-1β)和一氧化氮(NO),在神经退行性疾病中发挥关键作用。 。 方法:鉴于上述情况,抑制小胶质细胞介导的神经炎症被认为是神经退行性疾病的治疗策略。据报道,几种潜在的中草药提取物对特异性靶向活化的小胶质细胞的神经退行性疾病发挥神经保护作用。在这方面,酚类葡萄糖苷天麻素是中草药天麻的主要成分,在当地社区广泛产生,通过抑制神经毒性促炎介质显示出潜在的神经保护作用。 结果:在这里,我们首先回顾激活的小胶质细胞在不同脑疾病中的作用。然后考虑天麻素对活化的小胶质细胞的影响。我们已经将天麻素鉴定为推定的治疗剂,因为已发现其可抑制小胶质细胞活化,从而改善神经炎症。更重要的是,天麻素下调肾素血管紧张素系统(RAS)的表达和促炎介质的产生。值得注意的是,天麻素促进Sirtuin 3(Sirt3)上调和烟酰胺腺嘌呤二核苷酸磷酸氧化酶-2(NOX-2)下调后激活的小胶质细胞中由AT1或AT2受体介导的血管紧张素II受体亚型,表明可能的分子RAS和Sirt3生存基因之间的联系。 结论:本综述总结了天麻素作用于活化小胶质细胞和其他草药化合物的有益作用。它在神经保护方面的功效与中国一些常见的草药产品一致。
关键词: 天麻素,活化小胶质细胞,肾素血管紧张素系统-Sirtuin 3信号,抗炎,神经保护,草药化合物。
Current Medicinal Chemistry
Title:Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Volume: 25 Issue: 42
关键词: 天麻素,活化小胶质细胞,肾素血管紧张素系统-Sirtuin 3信号,抗炎,神经保护,草药化合物。
摘要: Background: Activated microglia play a pivotal role neurodegenerative diseases by producing a variety of proinflammatory mediators including tumor necrosis factor-alpha (TNF-α), interleukin- 1beta (IL-1β) and nitric oxide (NO) that are toxic to neurons and oligodendrocytes.
Methods: In view of the above, suppression of microglia mediated neuroinflammation is deemed a therapeutic strategy for neurodegenerative diseases. Several potential Chinese herbal extracts have been reported to exert neuroprotective effects against neurodegenerative diseases targeting specifically at the activated microglia. In this connection, the phenolic glucoside gastrodin, a main constituent of the Chinese herbal medicine Gastrodia rhizoma, produced widely in the local community exhibits potential neuroprotective effects through suppression of neurotoxic proinflammatory mediators.
Results: Here, we first review the roles of activated microglia in different brain diseases. The effects of gastrodin on activated microglia are then considered. We have identified gastrodin as a putative therapeutic agent as it has been found to suppress microglial activation thus ameliorating neuroinflammation. More importantly, gastrodin downregulates the expression of renin angiotensin system (RAS) and production of proinflammatory mediators. Remarkably, gastrodin promotes Sirtuin 3 (Sirt3) up-regulation and nicotinamide adenine dinucleotide phosphate oxidase-2 (NOX-2) down-regulation after ischemichypoxia in activated microglia mediated by AT1 or AT2 receptors which are angiotensin II receptors subtypes, indicating a possible molecular link between RAS and Sirt3 survival genes.
Conclusion: This review summarizes the beneficial effects of gastrodin acting on activated microglia along with other herbal compounds. Its efficacy in neuroprotection is consistent with some common herbal products in China.
Export Options
About this article
Cite this article as:
Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation, Current Medicinal Chemistry 2018; 25 (42) . https://dx.doi.org/10.2174/0929867325666180214123929
DOI https://dx.doi.org/10.2174/0929867325666180214123929 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Interleukin-33 as a Biomarker in Predicting Neonatal Sepsis in Premature Infants
Combinatorial Chemistry & High Throughput Screening Impact of Buprenorphine on Learning and Memory Ability, Oxidative Status and Inflammation in the Hippocampus of Rats
Current Molecular Pharmacology Telomerase Modulation in Therapeutic Approach
Current Pharmaceutical Design Unique Structural Motif Supports Mannosylphospho Dolichol Synthase: An Important Angiogenesis Regulator
Current Drug Targets Regulatory T Cells and Allergic Disease
Inflammation & Allergy - Drug Targets (Discontinued) Simultaneously Determining Seven Second-Line Anti-TB Drugs by UHPLC- MS: Application for TDM in HIV-TB Patients
Current Pharmaceutical Analysis Comparison of Dietary Approaches to Treat Obesity Based on the Different Carbohydrate/Fat Content: Impact on Weight Loss and Lipid Profile
Current Nutrition & Food Science Pannexin Channels: The Emerging Therapeutic Targets
Current Drug Targets The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi
Current Topics in Medicinal Chemistry Gene Therapy for Ischemic Brain Diseases
Current Gene Therapy Gene Therapy for Haemophagocytic Lymphohistiocytosis
Current Gene Therapy Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Purification and Characterization of Nitric Oxide Synthase from Bovine Kidney and Investigating Drug-Induced Toxicities of Some Antibiotics on the Enzyme Activity
Current Enzyme Inhibition Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice
Current Pediatric Reviews The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism Periodontitis and Periodontal Disease - Innovative Strategies for Reversing the Chronic Infectious and Inflammatory Condition by Natural Products
Current Pharmaceutical Design Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia
Current Medicinal Chemistry Angiogenesis Inhibitors and Radiation in Multimodality Cancer Therapy: Preclinical and Clinical Studies
Current Angiogenesis (Discontinued) Investigation of Structural, Treatment, and Clinical Characteristics of COVID-19 Along with the Challenges Caused by its Prevalence
Infectious Disorders - Drug Targets Mode Action Prediction of Butein as Antibacterial Oral Pathogen against <i>Enterococcus faecalis</i> ATCC 29212 and an Inhibitor of MurA Enzyme: In Vitro and In Silico Study
Letters in Drug Design & Discovery